Cargando…

Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415

PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform co...

Descripción completa

Detalles Bibliográficos
Autores principales: Khairnar, Rahul, Pugh, Stephanie L., Sandler, Howard M., Lee, W. Robert, Villalonga Olives, Ester, Mullins, C. Daniel, Palumbo, Francis B., Bruner, Deborah W., Shaya, Fadia T., Bentzen, Soren M., Shah, Amit B., Malone, Shawn C., Michalski, Jeff M., Dayes, Ian S., Seaward, Samantha A., Albert, Michele, Currey, Adam D., Pisansky, Thomas M., Chen, Yuhchyau, Horwitz, Eric M., DeNittis, Albert S., Feng, Felix Y., Mishra, Mark V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046237/
https://www.ncbi.nlm.nih.gov/pubmed/33852571
http://dx.doi.org/10.1371/journal.pone.0249123
_version_ 1783678810220134400
author Khairnar, Rahul
Pugh, Stephanie L.
Sandler, Howard M.
Lee, W. Robert
Villalonga Olives, Ester
Mullins, C. Daniel
Palumbo, Francis B.
Bruner, Deborah W.
Shaya, Fadia T.
Bentzen, Soren M.
Shah, Amit B.
Malone, Shawn C.
Michalski, Jeff M.
Dayes, Ian S.
Seaward, Samantha A.
Albert, Michele
Currey, Adam D.
Pisansky, Thomas M.
Chen, Yuhchyau
Horwitz, Eric M.
DeNittis, Albert S.
Feng, Felix Y.
Mishra, Mark V.
author_facet Khairnar, Rahul
Pugh, Stephanie L.
Sandler, Howard M.
Lee, W. Robert
Villalonga Olives, Ester
Mullins, C. Daniel
Palumbo, Francis B.
Bruner, Deborah W.
Shaya, Fadia T.
Bentzen, Soren M.
Shah, Amit B.
Malone, Shawn C.
Michalski, Jeff M.
Dayes, Ian S.
Seaward, Samantha A.
Albert, Michele
Currey, Adam D.
Pisansky, Thomas M.
Chen, Yuhchyau
Horwitz, Eric M.
DeNittis, Albert S.
Feng, Felix Y.
Mishra, Mark V.
author_sort Khairnar, Rahul
collection PubMed
description PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities. METHODS AND MATERIALS: This is a secondary analysis of a prospective, randomized non-inferiority clinical trial, conducted between 04/2006 and 12/2009 at cancer centers across the United States, Canada, and Switzerland. Eligible patients included men >18 years with a known diagnosis of low-risk PC. Patient HRQoL data were collected using EPIC and health utilities were obtained using EQ5D. Data were divided into an estimation sample (n = 765, 70%) and a validation sample (n = 327, 30%). The mapping algorithms that capture the relationship between the instruments were estimated using ordinary least squares (OLS), Tobit, and two-part models. Five-fold cross-validation (in-sample) was used to compare the predictive performance of the estimated models. Final models were selected based on root mean square error (RMSE). RESULTS: A total of 565 patients in the estimation sample had complete information on both EPIC and EQ5D questionnaires at baseline. Mean observed EQ5D utility was 0.90±0.13 (range: 0.28–1) with 55% of patients in full health. OLS models outperformed their counterpart Tobit and two-part models for all pre-determined model specifications. The best model fit was: “EQ5D utility = 0.248541 + 0.000748*(Urinary Function) + 0.001134*(Urinary Bother) + 0.000968*(Hormonal Function) + 0.004404*(Hormonal Bother)– 0.376487*(Zubrod) + 0.003562*(Urinary Function*Zubrod)”; RMSE was 0.10462. CONCLUSIONS: This is the first study to identify a comprehensive set of mapping algorithms to generate EQ5D utilities from EPIC domain/ sub-domain scores. The study results will help estimate quality-adjusted life-years in PC economic evaluations.
format Online
Article
Text
id pubmed-8046237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-80462372021-04-21 Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 Khairnar, Rahul Pugh, Stephanie L. Sandler, Howard M. Lee, W. Robert Villalonga Olives, Ester Mullins, C. Daniel Palumbo, Francis B. Bruner, Deborah W. Shaya, Fadia T. Bentzen, Soren M. Shah, Amit B. Malone, Shawn C. Michalski, Jeff M. Dayes, Ian S. Seaward, Samantha A. Albert, Michele Currey, Adam D. Pisansky, Thomas M. Chen, Yuhchyau Horwitz, Eric M. DeNittis, Albert S. Feng, Felix Y. Mishra, Mark V. PLoS One Research Article PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities. METHODS AND MATERIALS: This is a secondary analysis of a prospective, randomized non-inferiority clinical trial, conducted between 04/2006 and 12/2009 at cancer centers across the United States, Canada, and Switzerland. Eligible patients included men >18 years with a known diagnosis of low-risk PC. Patient HRQoL data were collected using EPIC and health utilities were obtained using EQ5D. Data were divided into an estimation sample (n = 765, 70%) and a validation sample (n = 327, 30%). The mapping algorithms that capture the relationship between the instruments were estimated using ordinary least squares (OLS), Tobit, and two-part models. Five-fold cross-validation (in-sample) was used to compare the predictive performance of the estimated models. Final models were selected based on root mean square error (RMSE). RESULTS: A total of 565 patients in the estimation sample had complete information on both EPIC and EQ5D questionnaires at baseline. Mean observed EQ5D utility was 0.90±0.13 (range: 0.28–1) with 55% of patients in full health. OLS models outperformed their counterpart Tobit and two-part models for all pre-determined model specifications. The best model fit was: “EQ5D utility = 0.248541 + 0.000748*(Urinary Function) + 0.001134*(Urinary Bother) + 0.000968*(Hormonal Function) + 0.004404*(Hormonal Bother)– 0.376487*(Zubrod) + 0.003562*(Urinary Function*Zubrod)”; RMSE was 0.10462. CONCLUSIONS: This is the first study to identify a comprehensive set of mapping algorithms to generate EQ5D utilities from EPIC domain/ sub-domain scores. The study results will help estimate quality-adjusted life-years in PC economic evaluations. Public Library of Science 2021-04-14 /pmc/articles/PMC8046237/ /pubmed/33852571 http://dx.doi.org/10.1371/journal.pone.0249123 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Khairnar, Rahul
Pugh, Stephanie L.
Sandler, Howard M.
Lee, W. Robert
Villalonga Olives, Ester
Mullins, C. Daniel
Palumbo, Francis B.
Bruner, Deborah W.
Shaya, Fadia T.
Bentzen, Soren M.
Shah, Amit B.
Malone, Shawn C.
Michalski, Jeff M.
Dayes, Ian S.
Seaward, Samantha A.
Albert, Michele
Currey, Adam D.
Pisansky, Thomas M.
Chen, Yuhchyau
Horwitz, Eric M.
DeNittis, Albert S.
Feng, Felix Y.
Mishra, Mark V.
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
title Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
title_full Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
title_fullStr Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
title_full_unstemmed Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
title_short Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
title_sort mapping expanded prostate cancer index composite to eq5d utilities to inform economic evaluations in prostate cancer: secondary analysis of nrg/rtog 0415
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046237/
https://www.ncbi.nlm.nih.gov/pubmed/33852571
http://dx.doi.org/10.1371/journal.pone.0249123
work_keys_str_mv AT khairnarrahul mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT pughstephaniel mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT sandlerhowardm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT leewrobert mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT villalongaolivesester mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT mullinscdaniel mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT palumbofrancisb mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT brunerdeborahw mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT shayafadiat mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT bentzensorenm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT shahamitb mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT maloneshawnc mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT michalskijeffm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT dayesians mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT seawardsamanthaa mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT albertmichele mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT curreyadamd mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT pisanskythomasm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT chenyuhchyau mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT horwitzericm mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT denittisalberts mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT fengfelixy mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415
AT mishramarkv mappingexpandedprostatecancerindexcompositetoeq5dutilitiestoinformeconomicevaluationsinprostatecancersecondaryanalysisofnrgrtog0415